DX / Differentials / DERMATOLOGY GROUPS

D-02 — NEW PATIENT VOLUME · DERMATOLOGY GROUPS

New patient volume is short of plan — dermatology

The demand is already in the building

DIFFERENTIAL — LIKELY CAUSES, MOST LIKELY FIRST

1. 01

   [COS] Consult-to-treatment conversion is not measured as a stage, so it cannot be managed as one

   The cosmetic line treats a consult like a visit — something that happened. It is actually the conversion event, and the practice is paying for every one that doesn't convert. Where it isn't counted, a soft close rate reads as a thin pipeline.

   Top-performing aesthetics practices close 58% of consults and convert 42% of inbound leads into a booked consult, for 24% end to end. CorralData is explicit that this is the top-performer benchmark rather than the cohort average — the typical practice sits below it. Practices with genuinely thin demand and practices with a soft consult look identical on a revenue report and completely different on a three-stage funnel.

   CorralData Research, Q1 2026 Aesthetics Industry Benchmark. Cohort explicitly excludes dermatology and plastic surgery centers — labelled proxy. CorralData also asserts a "~20% industry benchmark" for lead-to-consult with no cited primary; that number does not publish and is not used here.

   NOT THIS IF — You already track consult-to-treatment weekly and it sits above 50%. Then the constraint is upstream of the consult and the acquisition question is legitimate.

2. 02

   [COS] Nobody rebooks at the chair, so the pipeline is rebuilt from zero every cycle

   The next appointment is either made before the guest leaves or it is bought again later at full media price. Rebooking is the cheapest pipeline in aesthetics and it is a script, not a system.

   Medspas rebook 40% of guests within 24 hours on average; top earners rebook 69%, and the top quartile 54%. The compounding is where it gets decisive: among locations where guests were rebooked once, 37% of those appointments cancelled — guests rebooked two or more times cancel at just 4%. A nine-fold difference between the first rebooking and the second. Medspa no-show rate is 5%, the highest of any business type on the platform.

   Zenoti, 2025 Beauty & Wellness Benchmark Report (CY2024) for rebooking and no-show; 2026 edition (CY2025) for the rebooking-to-cancellation relationship. Aggregated platform transaction data, North America.

   NOT THIS IF — Your 24-hour rebooking rate is already above 54%. Then rebooking is not the leak and you should look at consult conversion or at new-guest supply.

3. 03

   [COS] The practice makes people call, and the highest-intent demand won't

   Booking friction sits between existing demand and a filled column, and it is built into the booking step itself — call during business hours, wait, leave a message. It is invisible on a marketing report because the inquiry that never happened produces no record.

   Median medspa online booking rate is 13%, against 18% at the 75th percentile and 32% at the 90th. In adjacent salon data — labelled as adjacent, not medspa — clients who book their first appointment online return for a second appointment 78% of the time, compared to 39% for walk-ins; only 45% of clients return after a first appointment at all, and just 13% of retail sales happen during the first appointment.

   Zenoti 2026 Benchmark Report (CY2025) for online booking. Salon comparison: Boulevard salon retention report, Oct 2023 — more than 11 million appointments and 4 million unique clients across more than 2,500 businesses (Jan 2022–Mar 2023). That second source is salons, not medspas, and is included only with that label.

   NOT THIS IF — Online booking is already above 18% of your cosmetic volume and consult slots still go empty. The friction is downstream — look at what happens after the booking.

4. 04

   The medical panel is never offered the cosmetic line — the cheapest pipeline in aesthetics goes unworked

   A dermatology practice is the only operator in aesthetics with a medical panel already walking through the door — which is why dermatology's medical and cosmetic lines have to be read against each other rather than separately. Where the two lines run as separate businesses with separate intake and no handoff, the practice buys cosmetic demand in an auction while the same demand sits in its own waiting room.

   The median dermatologist carries 496 Medicare beneficiaries before a single marketing dollar. 70% of consumers say they are considering a cosmetic procedure, and dermatologists are the physician of choice in 12 procedure categories with 95%+ satisfaction in 8 of 15 treatments. The clinical capacity for the handoff already exists: 74% of dermatology PAs offer cosmetic services, and a dermatology PA performs a median 42 full-body skin exams per week.

   CMS PUF by Provider, CY2024 (Medicare panel, Medicare-only); ASDS 2025 Consumer Survey (n > 3,500 consumers — intent, not transactions); SDPA 2024 Practice Survey Report of Dermatology PAs, n=994, self-selected members. No published figure exists for medical-to-cosmetic conversion inside a dermatology practice; this cause is asserted from the components, and we say so.

   NOT THIS IF — You already run a documented cross-line handoff with a counted conversion rate. Then this is instrumented and the pipeline question is genuinely on the cosmetic side.

5. 05

   [MED] Referrals and surveillance recalls leak, and the leak has no owner

   Medical dermatology demand arrives as a referral or a due date, and both die in scheduling. Nothing about a thin surgical block looks like a marketing problem, which is exactly why it stays unfixed.

   The best-documented referral leak in the literature is not dermatology's — it is a single integrated health system, where of 103,737 referral scheduling attempts only 34.8% were completed and 38.9% had no documented status at all. Read it as a cross-specialty warning about what referral handling does when nobody owns it, not as a dermatology figure. On the dermatology side, the concentration is stark: Mohs first stage is 1,140,695 services nationally against 12,701,462 destructions of premalignant lesions beyond the first — the surgical block is the scarce, high-fee asset and it is the one referrals feed.

   Patel MP, Schettini P, O'Leary CP, Bosworth HB, Anderson JB, Shah KP, "Closing the Referral Loop," J Gen Intern Med 2018 — an integrated health system, explicitly not dermatology. CMS PUF by Geography and Service, CY2024 for the volume comparison.

   NOT THIS IF — Referrals are logged, statused and reconciled, and the overdue-surveillance list is a number your practice can produce today. Then the loop is closed.

HOW TO TELL THEM APART

How to tell these apart in your own numbers

Each of these is a measurement you can run yourself, without us.

WHAT RESOLVES EACH

What resolves this, and how you will know it resolved

[COS] Consult-to-treatment conversion is not measured as a stage, so it cannot be managed as one	Rx 03 · patient conversion →	Frank version: if consult-to-treatment is unmeasured, do not buy media. Every additional dollar is spent to produce more of the event you are losing.
[COS] Nobody rebooks at the chair, so the pipeline is rebuilt from zero every cycle	Rx 03 · patient conversion →	This one does not require us. It is a script, a calendar and someone whose job it is. Nothing on this page has a better return on effort than getting to a guest's second rebooking.
[COS] The practice makes people call, and the highest-intent demand won't	Rx 02 · medical practice websites →	Online booking on the cosmetic line, with the consult defined and priced on the page. What does not work: a contact form that promises a callback, in a category where the top performers respond in about two hours.
The medical panel is never offered the cosmetic line — the cheapest pipeline in aesthetics goes unworked	Rx 03 · patient conversion →	The handoff is an operational design problem — who offers, at what point in the visit, with what consent boundary between an insurance encounter and a cash-pay offer. That boundary is the reason most practices never build it, and it is a real constraint, not an excuse.
[MED] Referrals and surveillance recalls leak, and the leak has no owner	Rx 04 · marketing attribution →	Status every referral and produce the overdue-surveillance list weekly. Cheapest demand in the practice, and the one nobody is bidding against you for.

• Rx 01 · patient acquisition — Acquisition is the last step in this differential, not the first. We do not scale spend into a funnel that has not been decomposed.

HOW THIS DIFFERS BY SCALE

How this differs by scale

Single site	Every test here is runnable in a week by the practice itself, and three of the fixes are free. A single site with a 40% rebooking rate and no online booking has more recoverable pipeline inside the building than any campaign will produce outside it.
Group	Conversion varies by injector more than by market, and the group number hides it. Run consult-to-treatment per injector before running it per site — the spread inside a site is usually wider than the spread between sites.
Platform	At platform scale the cross-line handoff is the asset no competitor can copy: a medical panel feeding a cash-pay line, at scale, with a documented conversion rate. Almost nobody has built it, which is why almost nobody can price it in a process.

OTHER PRESENTATIONS — DERMATOLOGY GROUPS

• The schedule is full and the number stopped moving
• Cost per consult is climbing — and cost per encounter was never measured
• Same brand, same fee schedule, four-fold spread
• How much of this survives the surgeon leaving the room?